Ray Gilmartin 2002 Alumni Achievement Award

Under the circumstances you might wish to withdraw this award. At least better sceening is in order See below:

Business Week Online


Raymond Gilmartin

No doubt Merck & Co. (MRK ) Chairman and CEO Raymond V. Gilmartin would prefer to forget 2004, when the drugmaker had to withdraw Vioxx — its painkiller that was hauling in $2.5 billion in annual sales. But while last year was tough, Merck will be paying the price for the Vioxx disaster for years to come.

Although critics had been warning for years that Vioxx might be dangerous, Gilmartin and his team had argued the drug was safe, and they continued to promote it aggressively. But in late September, a Merck study confirmed the drug raised the risk of heart attack and stroke. Merck is facing hundreds of lawsuits over Vioxx and is likely to get hit with many more. Sanford C. Bernstein & Co. (AL ) analyst Richard T. Evans warns that the legal liability could exceed $25 billion.

A bill that high will limit Merck’s financial flexibility. While Gilmartin has stepped up the pace of licensing and product acquisition — striking about 50 licensing deals in 2004, up from just 10 in 1999 — it may be too little, too late. In 2006 the company will lose U.S. patent protection on its $5 billion cholesterol-lowering drug Zocor. And while Merck has some interesting products in its pipeline, they’re unlikely to be large enough to offset the loss. No wonder Merck’s stock is off about 30% since the Vioxx withdrawal.

Gilmartin has also resisted the industry trend of drug-company megamergers. While there is no evidence those deals improve research and development productivity, they do offer cost savings opportunities and new products to help companies manage through lean times. And while Merck could have done a deal years ago from a position of strength, its weak stock price and likely huge legal liability now make it an unattractive partner.

With the 63-year-old Gilmartin preparing to retire in the spring of 2006, Merck’s board has started searching for his replacement. Some disgusted investors would like to see Gilmartin step down early. But in the wake of the mess, directors may struggle to recruit someone to fix the ailing drugmaker.

More Evil Behavior from Merck

By Dr. Joseph Mercola
with Dr. Daniel Chong

The amazing disregard for public health by many drug companies has been chronicled on this site for a number of years now. Additionally, Dr. Angell, a former editor of the New England Journal of Medicine and major “insider,” has written the single best book on this topic, and it is highly recommended if you have any interest in this area.

If you read Dr. Angell’s book or many of the articles I have run on this site detailing this evil behavior, I sincerely believe that Merck would receive the winning prize for the ‘most serious disregard of ethical behavior that has influenced the largest number of people.’ In case you’re not familiar with them, they are the company that killed over 55,000 people with their drug Vioxx.

This is really sad as Merck has a long-standing history of being at the forefront of the entire drug industry for providing leadership and high ethical standards. It is unclear to me why they developed such sordid business practices in recent years.

Statin Drugs and CoQ10

While Lipitor is clearly the market leader for statin drugs, many may not realize that Merck started this market by introducing Mevacor and then Zocor. They have been passed up by Pfizer, though, with Lipitor.

While the statin drugs millions of Americans are taking are certainly effective at what they do, very few people realize that they can be equally as dangerous. Well-recognized, potential side effects printed in safety information for each drug include liver dysfunction, muscle disease and kidney failure.

An equally problematic, yet lesser known, danger of statin drugs involves their ability to block the production of CoQ10 in your body. Found naturally in meats, in particular beef heart, CoQ10 is also a popular dietary supplement used mostly for boosting energy, stamina and heart function. CoQ10 is a vital nutrient, possessing powerful antioxidant capabilities, and is essential for cellular energy production in every cell of your body, particularly your heart and liver.

Dr. Julian Whitaker, world-renowned author, nutritional expert and co-founder–along with Dr. Linus Pauling–of the California Orthomolecular Medical Society, states that, “Patients who take statin drugs without CoQ10, particularly those with a history of heart disease, are especially prone to developing complications that can have fatal consequences.”

Merck’s Shenanigans Unveiled Again

While never widely publicized, this negative effect of statin drugs on CoQ10 levels has actually been known for years. In fact, according to Dr. Whitaker, in 1989 and 1990 Merck felt these effects were so clearly important that they actually patented the use of CoQ10 in combination with statin drugs. Products containing this important combination should have hit the market soon afterward. However, Merck chose not to exercise these patents, nor to help educate doctors and patients on the potential dangers of ingesting statins without CoQ10.

“I’m at a loss as to why Merck refuses to exercise these patents or, at the very least, add a warning label describing the potentially detrimental effects of not taking CoQ10 with its statin products,” Whitaker said.

One of Merck’s patents actually states, “Since CoQ10 … is of benefit in congestive heart failure patients, the combination with HMG-CoA reductase inhibitors (statin drugs) should be of value in such patients who also have the added risk of high cholesterol.” Amazingly, this patent was filed on June 12, 1990, and yet no drug reflecting this combination has ever been produced!

An equally infuriating phenomenon is that, to this day, even with the popularity and prescription numbers of statins soaring into the stratosphere, many prescribing physicians and their patients remain ignorant about these important findings.

In an effort to remedy this tragic situation three years ago, Dr. Whitaker wrote a petition to the Food and Drug Administration (FDA) to insist that all manufacturers of statin drugs include warning labels with these medications, describing the importance of supplementing CoQ10 along with their prescriptions. In his petition, Dr. Whitaker recommends the “use of 100 to 200 mg per day of supplemental CoQ10, to reduce the risk of statin-induced myopathies (muscle diseases), which include cardiomyopathy and congestive heart failure.”

As of yet, no such warning labels have been put to use.

More Merck Mischief

If the preceding information has helped enlighten you as to the wayward behavior of Merck & Co., please also be aware that this has not been their only foray down low-integrity pathways.

The following incidents have also been chronicled on this site. If you would like to read the full stories summarized below, be sure to click on the highlighted text within each description:

In 1991, nearly a decade before the first public disclosure, a memo from Merck showed senior executives were concerned that infants were getting an elevated dose of mercury in vaccinations containing the preservative thimerosal. The memo disclosed that 6-month-old children who received their shots on schedule would be receiving a mercury dose nearly 87 times higher than guidelines for the maximum daily consumption of mercury from fish. In addition, it included the following recommendation: whenever possible, particularly among use in infants and young children, vaccines with mercury should be eliminated.

In September 1999, amidst concerns about the risks of mercury in childhood vaccines, Merck stated that the FDA had approved a preservative-free version of their vaccine. And, despite Merck’s news release at that time
, which stated, “Now Merck’s infant vaccine line is free of all preservatives,” the company continued to distribute vaccines containing thimerosal until October 2001.

Undisclosed company documents also show that Merck was in the process of beginning a major cardiovascular study of the drug Vioxx, which the public now knows can cause serious cardiovascular side effects, in 2002. However, Merck suddenly dropped the project just before it was set to start. The data from this study, which would have been released by March 2004, may have provided answers about Vioxx’s risks even earlier. It was not until September 2004 that Merck put a stop to a separate study when patients in that trial experienced heart attacks and strokes at twice the rate of those receiving a placebo.

While it would be difficult to argue that any major drug company actually holds your health as its number-one priority, Merck’s behavior clearly identifies them as one of the most ethically compromised drug companies. If you are a person who buys stocks, you might want to avoid purchasing their stock. But wait, you might know that already since they lost nearly $30 billion (more than 25 percent of the company’s value) after the Vioxx risks were uncovered and stand to lose another $20 billion in the upcoming lawsuits.

Seems like they are reaping the fruits of the evil behavior they have sown over the years.

Dr. Daniel Chong is a licensed naturopathic physician practicing in Portland, OR. His practice focuses on the use of nutrition and herbal medicine in the management of chronic illnesses. He may be contacted at:

Chiropractic and Naturopathic Physicians Clinic
12195 SW Allen Blvd.
Beaverton, OR 97005
(503) 646-0697


Whitaker, J.M., M.D. Citizen petition before the Department of Health and Human Services Food and Drug Administration, November 24, 2002.

Brown, M.S. Coenzyme Q. sub. 10 with HMG-CoA reductase inhibitors. United States Patent 4,933, 165. June 12, 1990.

May 9, 2005
Want to Sponsor The Harbus?

You can sponsor the Harbus website to reach the Harvard Community. Learn more.


We are addicted to WordPress development and provide Easy to using & Shine Looking themes selling on ThemeForest.

Tel : (000) 456-7890
Email :